louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02530190: Investigation of Popular Recovery Techniques for Ultramarathon Recovery
Official title: Investigation of Popular Recovery Techniques for Ultramarathon Recovery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Pain
Lead sponsor: Western States Endurance Run Research Foundation
Sponsor class: OTHER
First posted: 2015-08-20
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a randomized clinical trial examining the effectiveness of massage and intermittent pneumatic compression on recovery from a 161-km ultramarathon.

Detailed description: The study is a randomized clinical trial examining the effectiveness of massage and intermittent pneumatic compression on recovery from a 161-km ultramarathon. Participants of the 2015 161-km Western States Endurance Run were randomized to a 20-minute post-race intervention of massage, intermittent pneumatic compression or supine rest. Each subject completed two 400 m runs at maximum speed before the race, and on days 3 and 5 after the race, and also provided muscle pain and soreness ratings and overall muscular fatigue scores before and for 7 days after the race.

Eligibility criteria: Inclusion Criteria:

* Entry in the Western States Endurance Run

Exclusion Criteria:

* Failure to finish race

Primary outcomes:
measure: 400 m run time
timeFrame: 5 days
Secondary outcomes:
measure: Lower body muscle pain and soreness rating
timeFrame: 5 days
measure: Overall muscular fatigue score
timeFrame: 5 days
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: VA Northern California Health Care System
state: California
Study officials:
References:
citation: Hoffman MD, Badowski N, Chin J, Stuempfle KJ. A Randomized Controlled Trial of Massage and Pneumatic Compression for Ultramarathon Recovery. J Orthop Sports Phys Ther. 2016 May;46(5):320-6. doi: 10.2519/jospt.2016.6455. Epub 2016 Mar 23.
Clinical trial NCT06131190: Effect Mindfulness Training on Attention, Hyperactivity and Emotion Regulation Among Children With ADHD:
Official title: Effect Mindfulness Based Training on Attention, Hyperactivity and Emotion Regulation Among Children With ADHD: A Randomized Controlled Trails
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: A
Keywords: Mindfulness
ADHD
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2023-11-14
Enrollment: 50
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Effect Mindfulness Based Training on Attention
Primary purpose: SUPPORTIVE_CARE

Brief summary: Mindfulness training is a promising form of training for children with ADHD, as it focuses on attention and has gained empirical support as a complementary or alternative intervention. It involves increasing awareness and nonjudgmental observation of present-moment experiences while reducing automatic responding

Detailed description: training to sustain focus on present-moment experiences and gently shifting attention back to the meditation object when the mind drifts (Bishop, et al., 2004). Mindfulness meditation is a relatively new approach for reducing stress and emotion regulation difficulties among children. While researching the efficacy of mindfulness training in children is a new domain, existing evidence suggests that it has positive effects on psychological well-being, pain management, emotion dysregulation, negative behaviors, and cognitive/executive functions and attention (Evans et al., 2018; Zhang, Díaz-Román, \& Cortese,2018).

Nurses have an important role in caring for children with ADHD, particularly in the context of mindfulness-based interventions. They can provide education and support to both parents and children regarding the benefits of mindfulness practice and can help implement mindfulness programs in clinical and community settings.

Eligibility criteria: Inclusion Criteria:

* age from 10-18 years old
* diagnosed with ADHD

Exclusion Criteria:

* age less than 10

Primary outcomes:
measure: study group
timeFrame: three months
Secondary outcomes:
measure: study group
timeFrame: 3 monthes
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Mohamed Husien
state: Please Select A Country
Study officials:
References:
Clinical trial NCT00299390: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Official title: Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Small Cell Lung Carcinoma
Keywords: Sagopilone
Epothilone
SCLC
Small Cell Lung Cancer
Lung Cancer
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2006-03-06
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer

Detailed description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically proven Small-cell lung cancer (SCLC)
* Stage of extensive disease defined by the presence of distant metastases
* At least 1 unidimensionally measureable lesion
* WHO performance status 0 to 1
* No previous SCLC-related chemotherapy
* No previous SCLC-related surgery
* No previous radiotherapy (excepting for brain metastasis)
* Adequate function of major organs and systems

  * Nervous system

    * No Grade 2 or greater peripheral neuropathy
  * Cardiovascular:

    * No symptomatic congestive heart failure
    * No unstable angina pectoris
    * No arrythmia needing continuous treatment
    * No other uncontrolled concurrent illness

Exclusion Criteria:

* Superior vena cava syndrome or obstruction of any vital structure
* Untreated malignant hypercalcemia
* Pleural effusion as the only manifestation of disease
* Extensive disease amenable to radiation therapy
* Symptomatic brain metastases requiring whole brain irradiation
* Any concomitant malignancy excepting non-melanoma skin cancer or carcinoma in situ of the cervix

Primary outcomes:
measure: Response to treatment according to the modRECIST (complete response or partial response)
timeFrame: Every 2 cycles until tumor progression i.e. approximately every 6 weeks
Secondary outcomes:
measure: Duration of complete or partial tumor response
timeFrame: Every 2 cycles until tumor progression i.e. approximately every 6 weeks
measure: Time to tumor progression
timeFrame: Every 2 cycles until tumor progression i.e. approximately every 6 weeks
measure: Number of participants with adverse events
timeFrame: Approximately 30 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00322790: Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study
Official title: INST 0549C Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Cancer
Lead sponsor: New Mexico Cancer Research Alliance
Sponsor class: OTHER
First posted: 2006-05-08
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals diagnosed with malignant germ cell tumors at University of New Mexico facilities

Brief summary: Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females.

Detailed description: Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study.

Eligibility criteria: Inclusion Criteria:

* Survival for Malignant Germ Cell Tumors in Males and Females.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Harriet Smith, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04567290: Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome
Official title: Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Acute Coronary Syndrome
Keywords: Ticagrelor
Platelet aggregation inhibitors
VerifyNow
Acute coronary syndrome
Lead sponsor: Centro Hospitalario La Concepcion
Sponsor class: OTHER
First posted: 2020-09-28
Enrollment: 50
Sex: ALL
Minimum age (years): 19
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention


Eligibility criteria: Inclusion Criteria:

* All patients presenting to the emergency department with acute coronary syndrome for percutaneous coronary intervention

Exclusion Criteria:

* Age \<18 years
* Known coagulopathy, bleeding diathesis, or active bleeding
* History of recent gastrointestinal or genitourinary bleeding within 2 months
* Previous therapy with clopidogrel, prasugrel, or ticagrelor
* Previous treatment with glycoprotein IIb/IIIa inhibitors or during interventional procedure
* Major surgery within 6 weeks
* History of intracranial bleeding or intracraneal neoplasm
* Suspected aortic dissection
* Chronic obstructive pulmonary disease
* Severe hemodynamic instability or cardiogenic shock
* Resuscitated cardiac arrest
* Use of vitamin K anticoagulants or novel oral anticoagulants (NOACs) within 7 days
* Life expectancy \<1 year
* Known severe liver or renal disease, GFR estimated by CKD-EPI \<30 ml/min/1.73 m2
* Known HIV treatment
* Hemoglobin \<10 g/dL
* Platelet count \<100,000/L
* Pregnancy
* Known allergy to ticagrelor
* Refusal to sign informed consent

Primary outcomes:
measure: Platelet reactivity
timeFrame: 1 hour
Secondary outcomes:
measure: Efficacy (MACCE)
timeFrame: 30 days
measure: Composite outcome
timeFrame: 30 days
measure: Efficacy (long term)
timeFrame: 1 year
measure: High platelet reactivity on treatment rate
timeFrame: 1 hour
Other outcomes:
Locations:
city: Saltillo
country: Mexico
facility: Hospital La Concepción
state: Coahuila
Study officials:
References:
Clinical trial NCT01842490: Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery
Official title: Can Serum Biomarker of Plaque Vulnerability be Identified Through the Contrast-enhanced Ultrasound of Carotid Artery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraplaque Neovascularization Evaluated by Carotid Enhanced Ultrasound Well Reflect the Plaque Vulnerability
Keywords: Biomarker
Carotid enhanced ultrasound
Intraplaque neovascularization
Lead sponsor: Kyunghee University Medical Center
Sponsor class: OTHER
First posted: 2013-04-29
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients were selected from those who admitted due to chest pain and underwent carotid duplex ultrasound examination at KyungHee university medical center, Seoul, South Korea.

Brief summary: No serum biomarker has qualified for clinical use until now. However several biomarkers, especially markers of inflammatory or proteolytic activity seem to promising in the identification of vulnerable plaques. Moreover, recent study confirmed that contrast-enhanced ultrasound imaging(CEUS) can visualize intraplaque neovascularization and represent the plaque vulnerability. In this study we try to identify indicators through analysis of the relationship between plaque neovascularization seen by CEUS and well known biomarkers such as serum matrix metalloproteinase(MMP)-2, MMP-9, cathepsin family(L,S,V), cystatin C, lipoprotein phospholipase A2, and hs-crp


Eligibility criteria: Inclusion Criteria:

* patients with carotid plaques size more than 2mm by carotid ultrasound

Exclusion Criteria:

* known allergy to albumin, or to the ultrasound contrast agent
* the patients with history of carotid endarterectomy and carotid stent
* acute myocardial infarction, cardiogenic shock
* connective tissue disease and malignancy
* creatinine clearance lower than 30ml/min and the history of dialysis

Primary outcomes:
measure: Peak plasma concentration of Biomarker that is statistically significant different according to the presence of intraplaque neovascularization on contrast enhanced ultrasound of carotid artery
timeFrame: after performing contrast enhanced ultrasound of carotid artery, upto 3 hospital days
Secondary outcomes:
measure: the number of the patients with history of cardiovascular event including myocardial infarction, cerebral vascular event and peripheral arterial disease and the number of 1 year clinical outcome of cardiovascular event
timeFrame: after performing contrast enhanced ultrasound of carotid artery, upto 1 year clinical follow up
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Cardiology, Department of Internal Medicine, Kyung Hee University School of Medicine
Study officials:
References:
Clinical trial NCT00222690: Living With Fibromyalgia: Triggers,Subgroups, and a Cognitive-Behavioral and Interactive Technology-Based Intervention
Official title: Living With Fibromyalgia (FM): Triggers,Clinical Subgroups, and the Effects Of A Self-Monitored Cognitive-Behavioral and Interactive Technology-Based Intervention on Clinical Subgroups
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia
Keywords: qualitative interview
symptom triggers
activity and participation
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: SHRS Research Development Fund
name: U.S. Department of Education
First posted: 2005-09-22
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: OTHER

Brief summary: The purpose of this study is to conduct semi-structured qualitative interviews to examine the personal experiences of women living with fibromyalgia. The specific aims of this study are to identify clinically relevant "triggers" of fibromyalgia symptoms and examine their impact on activity limitations and participation restrictions.

Detailed description: Fibromyalgia (FM) may currently be the most common rheumatic diagnosis of rheumatologists among their female patients, with 15-20% of all new rheumatology referrals meeting the 1990 American College of Rheumatology (ACR) diagnosis criteria for fibromyalgia. People with fibromyalgia live through widespread musculoskeletal chronic pain, fatigue, psychological distress, and exhibit diminished physical performance due in part to the cycle of pain that adversely affect their activity participation and overall well-being.

The purpose of this prospective mixed methods study is to conduct semi-structured qualitative interviews using ethnographic techniques to examine the personal experiences of women living with fibromyalgia. The specific aims of this study are to identify clinically relevant "triggers" of fibromyalgia symptoms and examine their impact on activity limitations and participation restrictions.

Eligibility criteria: Inclusion Criteria:

(1)At least 18 years of age; (2) meet the American College of Rheumatology (ACR) criteria for FM as diagnosed by a physician; (3) have been diagnosed with FM at least 1 year prior to admission to the study; (4) have sufficient vision, based on a functional vision test (i.e., read newsprint) to operate a computer program; (5) speak English; and (6) have a private telephone line.

Exclusion Criteria:

(1)Living beyond a 40-mile radius from the Oakland campus of the University of Pittsburgh. (2)Disability in everyday tasks related to a diagnosis other than FM (e.g., stroke, Parkinson disease) will also be grounds for exclusion.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh - Department of Occupational Therapy
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Hazel L Breland, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06188390: Hydrodissection in Carpal Tunnel Syndrome
Official title: Comparing Efficacy of Hydrodissection With Hyaluronic Acid vs 5% Dextrose for Carpal Tunnel Syndrome: A Randomized Controlled Trial and Ultrasonographic Evaluation of Median Nerve Gliding
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Carpal Tunnel Syndrome
Keywords: carpal tunnel syndrome
hydrodissection
ultrasonography
median nerve gliding
Lead sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Compare the efficacy on carpal tunnel syndrome (CTS) treatment between hydrodissection with hyaluronic acid (HA) vs 5% dextrose

Detailed description: Compare the efficacy on carpal tunnel syndrome treatment between hydrodissection with hyaluronic acid vs 5% dextrose through ultrasonographic evaluation.; 2) Evaluate the association of median nerve gliding results between using duplex Doppler ultrasound and B mode video with cross-correlation algorithm.

Eligibility criteria: Inclusion Criteria:

* 20-80 years old patients with carpal tunnel syndrome

Exclusion Criteria:

* pregnancy, Diabetes, hypothyroidism, uremia, rheumatoid arthritis, coagulopathy, cervical radiculopathy and patients who has ever received surgery for carpal tunnel syndrome or wrist fracture

Primary outcomes:
measure: Boston CTS (carpal tunnel syndrome) questionnaire
timeFrame: before injection , 2 weeks, 3 months and 6 months after injection.
Secondary outcomes:
measure: Ultrasonography (B mode) of median nerve
timeFrame: before injection , 2 weeks, 3 months and 6 months after injection.
measure: Ultrasonography (duplex Doppler) of median nerve
timeFrame: before injection , 2 weeks, 3 months and 6 months after injection.
measure: Nerve conduction study (NCS) of median nerve
timeFrame: before injection , 3 months and 6 months after injection.
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: Department of Physical Medicine and Rehabilitation, Taipei Tzu chi Hospital, Buddhist Tzu chi Medical Foundation
Study officials:
References:
citation: Lin MT, Liu IC, Syu WT, Kuo PL, Wu CH. Effect of Perineural Injection with Different Dextrose Volumes on Median Nerve Size, Elasticity and Mobility in Hands with Carpal Tunnel Syndrome. Diagnostics (Basel). 2021 May 9;11(5):849. doi: 10.3390/diagnostics11050849.
citation: Su YC, Shen YP, Li TY, Ho TY, Chen LC, Wu YT. The Efficacy of Hyaluronic Acid for Carpal Tunnel Syndrome: A Randomized Double-Blind Clinical Trial. Pain Med. 2021 Nov 26;22(11):2676-2685. doi: 10.1093/pm/pnab109.
citation: Babaei-Ghazani A, Moradnia S, Azar M, Forogh B, Ahadi T, Chaibakhsh S, Khodabandeh M, Eftekharsadat B. Ultrasound-guided 5% dextrose prolotherapy versus corticosteroid injection in carpal tunnel syndrome: a randomized, controlled clinical trial. Pain Manag. 2022 Sep;12(6):687-697. doi: 10.2217/pmt-2022-0018. Epub 2022 Jul 18.
Clinical trial NCT03892590: Gut Microbiota Pilot Study
Official title: Anaylsis of Gut Microbiota in ICU
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Microbiota
Metabolism
Lead sponsor: Armed Forces Goyang Hospital
Sponsor class: OTHER_GOV
First posted: 2019-03-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Stable adult patient who are admitted to ICU

Brief summary: Microbiota is known to effect metabolism. This is pilot study to get status of microbiota from normal control. It will be compared to data from specific patients in ICU via further study.

Detailed description: Microbiota is known to effect metabolism. Patients in specific conditions like hypovolemic shock, sepsis might have changes in status of microbiota. This is pilot study to get status of microbiota from normal control. Stable patient who are admitted to ICU for observation will be gathered. Samples will be collected via rectal swab at time of admission and analyzed via Next generation sequencing.

Eligibility criteria: Inclusion Criteria:

* Older than 17 years old
* Every patients who are admitted to ICU

Exclusion Criteria:

* With history of disease such as cancer, Crohn's disease, ulcerative colitis, irritable bowel syndrome
* With history of immunosuppressive agents.
* Initial systolic blood pressure \<100
* Initial pulse rate \> 100
* Need emergent operation at brain or torso
* Need vasopressor, transfusion

Primary outcomes:
measure: Normal microbiota
timeFrame: 1day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The Catholic University of Korea
name: Maru Kim, MD, PhD
role: STUDY_CHAIR
References: